Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.
Selwin, aged 30
Patient profile is fictional and for illustrative purposes only.
Are all your testicular cancer survivors routinely screened for symptoms of testosterone deficiency (TD)?
The European Society for Medical Oncology (ESMO) reports that hypogonadism is present in 11-35% of testicular cancer survivors.1 Therefore, in all patient follow up appointments post orchidectomy, ESMO recommends monitoring of total testosterone (TT), luteinizing hormone (LH) and follicle-stimulating hormone (FSH).1
The British Society for Sexual Medicine (BSSM) recommends an annual follow-up to monitor for long-term testicular cancer treatment-related side effects, including monitoring of testosterone and sex hormone binding globulin levels (SHBG).2
Men may not always mention all the symptoms of TD that they are experiencing. The Androgen Deficiency in Ageing Males (ADAM) questionnaire and the Ageing Males’ Symptoms (AMS) scale are simple and effective tools that can be quickly filled out during a patient appointment, to help you catch the symptoms of TD.3
TES/2020/009. April 2021.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: firstname.lastname@example.org
Testicular cancer and its treatment put patients at risk of developing TD. Find out about the consequences of TD.